검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Vinblastine Sulfate (Vinblastine Sulfate) Fondazione Italiana Linfomi - ETS·Lugano Classification Limited Stag… ORR 96% |
|---|---|
Overview Program | Vinblastine Sulfate |
Overview Company | Fondazione Italiana Linfomi - ETS |
Overview Modality | ADC |
Overview Target | Lugano Classification Limited Stage Hodg |
Overview Indication | Renal Pelvis and Ureter Urothelial Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeting histamine receptor |
MoA Biomarker | biomarkers-an 8 |
PK/PD Species | Mouse, Rat, thrombocytopenia (less than 200, 000 platelets/mm 3 ) |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Rational design of a stable W/O lipid emulsion for enhanced oral delivery of vinblastine.. The transition from intravenous to oral administration of vinblastine sulfate (VLB) poses a major clinical challenge, primarily due to its extremely low and variable oral bioavailability. To address these inherent limitations, we rationally designed a stable water-in-oil (W/O) lipid emulsion (VLB-LE) through… |
Clinical Primary efficacy | ORR 96% |
Clinical ORR | 96% |
Clinical Result source | ClinicalTrials.gov NCT00722865 |
Clinical Data Tier / Score | A · 69 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Vinblastine Sulfate (Vinblastine Sulfate) Fondazione Italiana Linfomi - ETS·Lugano Classification Limited Stag… ORR 96% |
|---|---|
Overview Program | Vinblastine Sulfate |
Overview Company | Fondazione Italiana Linfomi - ETS |
Overview Modality | ADC |
Overview Target | Lugano Classification Limited Stage Hodg |
Overview Indication | Renal Pelvis and Ureter Urothelial Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeting histamine receptor |
MoA Biomarker | biomarkers-an 8 |
PK/PD Species | Mouse, Rat, thrombocytopenia (less than 200, 000 platelets/mm 3 ) |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Rational design of a stable W/O lipid emulsion for enhanced oral delivery of vinblastine.. The transition from intravenous to oral administration of vinblastine sulfate (VLB) poses a major clinical challenge, primarily due to its extremely low and variable oral bioavailability. To address these inherent limitations, we rationally designed a stable water-in-oil (W/O) lipid emulsion (VLB-LE) through… |
Clinical Primary efficacy | ORR 96% |
Clinical ORR | 96% |
Clinical Result source | ClinicalTrials.gov NCT00722865 |
Clinical Data Tier / Score | A · 69 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교